In the realm of drug discovery, integral membrane proteins present a fascinating yet complex challenge. These proteins, despite comprising only a quarter of the human genome's proteins, are overrepresented as therapeutic targets, accounting for over half of all such targets. This is due to their pivotal role at the beginning of many signaling cascades and their accessibility on the cell surface, making them prime targets for biologic and small-molecule medications. However, working with membrane proteins is no easy feat, and it requires innovative approaches to overcome inherent challenges.
The Challenges of Membrane Proteins
One of the primary challenges is the low native expression of membrane proteins. Unlike soluble proteins, membrane proteins are confined to the limited 2D region of membranes, and each type may be expressed only in specific tissues or cell types, further complicating matters. To address this, researchers employ heterologous expression systems, such as E. coli for simple targets, insect cells for GPCRs, and mammalian systems for complex targets requiring proper glycosylation. Careful construct design and screening of multiple constructs and orthologs are crucial steps to enhance success rates.
Another challenge is the low stability, purity, and activity of membrane proteins. These proteins are inherently unstable outside their natural phospholipid bilayer environment, often unfolding or aggregating when extracted with detergents. To tackle this, researchers carefully select detergents to maintain protein folding and activity. Additionally, stabilized constructs and point mutations can increase yields and stability. Membrane mimetics like SMA, amphipols, peptidiscs, and nanodiscs offer an alternative by providing long-term stability without the need for destabilizing detergents. Alternatively, maintaining a membrane environment by reconstituting into liposomes can facilitate functional tests.
The limited expression and stability of membrane proteins often result in sub-milligram yields from many liters of protein. To overcome this, researchers employ highly sensitive biophysical techniques like SPR, GCI, and nanoDSF for interaction analysis, reducing protein consumption. Despite these challenges, membrane proteins remain promising targets for small chemical and biologic therapy development.
Structural Characterization and Beyond
Structural biology plays a crucial role in evaluating protein-protein and protein-small molecule interactions, enabling the rational design of therapeutic molecules through Structure-Based Drug Design (SBDD). However, membrane proteins pose unique challenges due to their flexibility, conformational heterogeneity, and instability over time, making it difficult to create well-ordered crystals for X-ray crystallographic structure determination. Suitable construct design, careful purification, and detailed biophysical characterization can improve the odds of structure identification, leading to more successful crystallographic outcomes.
Cryo-EM offers a promising alternative, eliminating the need for ordered crystal formation and allowing the determination of multiple structures from a single sample. This technique is particularly beneficial for large, flexible, full-length membrane proteins and multi-subunit complexes. Concept Life Sciences, a leading contract research organization, has extensive hands-on experience expressing, purifying, and characterizing these challenging membrane protein targets. Their services include construct design, protein production in various systems, purification using detergents and membrane mimetics, and a suite of QC, biophysical characterization, binding procedures, cryo-EM, and crystallography services.
In conclusion, while membrane proteins present significant challenges in drug discovery, innovative approaches and specialized services can help overcome these hurdles. The potential of membrane proteins as therapeutic targets is undeniable, and with the right tools and expertise, we can unlock their full potential in developing effective therapies.
